Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 9, 2025
Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
GlobeNewswire
·
April 9, 2025
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being …
PetMed Express, Inc. Announces Appointment of Peter Batushansky to Board of Directors
GlobeNewswire
·
April 9, 2025
Former pet industry executive with more than 20 years of experience across retail, pet, healthcare, and private equity Third independent director to join the Board since 2024 Longtime board member and former Chairman Dr. Gian Fulgoni will retire DELRAY …
World Leaders in Proteomics and Proteoform Biology to Convene at the 3rd International Top-Down Proteomics Symposium
GlobeNewswire
·
April 9, 2025
The Symposium will feature scientific leaders who are creating cutting edge technologies and approaches for building the bridge from genotype to phenotype. This is ushering in the era of proteoform-specific biology …
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
GlobeNewswire
·
April 9, 2025
CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025 PHILADELPHIA, April 09, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) ( …
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
GlobeNewswire
·
April 9, 2025
DUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today confirmed that April 11, 2025 will be the effective date for the Company’s previously announced Ratio Change on its American Depositary Shares (“ …
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
GlobeNewswire
·
April 9, 2025
FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy Total Revenue $19 million, representing +17% growth year over year FDA Approves Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA …
Theratechnologies présente ses résultats financiers pour le premier trimestre de 2025 et passe en revue ses principales réalisations
GlobeNewswire
·
April 9, 2025
La FDA approuve EGRIFTA WRMC (la formulation F8 de la tésamoréline) pour traiter l’excès de graisse viscérale abdominale chez les adultes vivant avec le VIH atteints de lipodystrophie Les revenus totaux s’élèvent à 19 millions de dollars, en hausse de 17 % …
Beta Bionics to Host Investor Event on June 22, 2025
GlobeNewswire
·
April 9, 2025
IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it will host an investor event on Sunday, June 22, …
Mars Veterinary Health Underscores Long-Term Commitment to Research & Innovation in Groundbreaking Science Impact Report
GlobeNewswire
·
April 9, 2025
BIRMINGHAM, England, April 09, 2025 (GLOBE NEWSWIRE) -- Today, Mars Veterinary Health published its inaugural Science Impact Report: Pets, Purpose …
Preliminary results for the year ended 31 December 2024
GlobeNewswire
·
April 9, 2025
~ Strong commercial momentum underpins transformative financial performance ~ Strong 2024 financial performance in line with guidance Revenue growth of 44% to £128.8 million compared to 2023, organic revenue growth of 81%1 Operating EBITDA2 loss of £(15.3) …
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
GlobeNewswire
·
April 9, 2025
Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, …
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
GlobeNewswire
·
April 9, 2025
WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies
GlobeNewswire
·
April 9, 2025
Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s genetically engineered pig organs in xenotransplantation Establishes framework for Makana’s kidney, heart and islet cell programs to …
Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub
GlobeNewswire
·
April 9, 2025
BROOMFIELD, Colo., April 09, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help …
Dentsply Sirona to Host First Quarter Conference Call on May 8th
GlobeNewswire
·
April 9, 2025
CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 8, 2025, at 8:30 am …
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
GlobeNewswire
·
April 9, 2025
WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the …
KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 Study for KSQ-004EX, a CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
GlobeNewswire
·
April 9, 2025
LEXINGTON, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1/2 clinical study of KSQ-004EX, a novel …
Microbix Exhibiting at ESCMID Global 2025
GlobeNewswire
·
April 9, 2025
MISSISSAUGA, Ontario, April 09, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending and exhibiting at ESCMID Global 2025 and that …
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET
GlobeNewswire
·
April 9, 2025
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. …
Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025
GlobeNewswire
·
April 9, 2025
ORION CORPORATION PRESS RELEASE 9 APRIL 2025 at 13.30 EEST Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025 Orion will publish Interim Report for January–March 2025 on Wednesday, 23 April 2025 at …